4
Expo 2025: Spirit of Innovation at the Swiss Pavilion in Osaka
Un document
plus
Actualités de Osaka
G20 Riyadh Summit Week: Women's Empowerment as a Key Enabler for Economic Recovery
Riyadh, Saudi Arabia (ots/PRNewswire) - A virtual roundtable was held during the summit week of the Saudi G20 Presidency on Women's empowerment as a key enabler for economic recovery. The round table featured Dr. Reham AlRassi, Policy Advisor Head of G20 Women's Empowerment, Dr. Hala AlTuwaijri, Chair of the Women Workstream, Mrs. Rania Nashar, CEO of Samba/Empower ...
plusStreet Parking or Garage: Price Implications For Parking Globally
- Insights from Parkopedia's 2019 Global Parking Index - Malaga, Spain (ots/PRNewswire) - - The 2019 Global Parking Index report is based on Parkopedia's own dataset, the most comprehensive and accurate parking database in the world, covering more than 70 million parking spaces across 15,000 cities in 89 countries. - The most expensive city for 2-hour off-street parking is New York, at an average of $34.94; - At an ...
plusPoor oral health severely impacts training and athletic performance, says FDI World Dental Federation
Geneva (ots) - If they want to win, elite and amateur athletes need to make their oral health a top priority. FDI World Dental Federation (FDI) couldn't agree more. Today the organization released a series of sports dentistry resources for amateur and elite athletes, dentists and sports medicine physicians, and sports organizations. The release coincides with a packed ...
plusChinese Shares to Rally Due to Central Bank Shift Says Chiba Taiko Partners
Osaka, Japan (ots/PRNewswire) - Chinese shares are now going to benefit a great amount as the country's central bank has increased measures to enable growth, within recent weeks sell-offs occurred in the market and it has now become apparent that there are some good investment opportunities arising according to Chiba Taiko Partners (https://www.ctpglobal.com/). The ...
plusTakeda Pharmaceutical Company Limited
Takeda Highlights Favorable Safety Profile of Entyvio® (vedolizumab) Through Comparative Real-World Data Versus TNFalpha-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease
Osaka, Japan (ots/PRNewswire) - Takeda demonstrates leadership in GI by featuring new U.S. VICTORY Consortium data among its 24 sponsored Entyvio abstracts presented at the Digestive Disease Week (DDW) 2018 meeting Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") today announced a new analysis of ...
plusTiGenix and Takeda Announce Alofisel® (darvadstrocel) Receives Approval to Treat Complex Perianal Fistulas in Crohn's Disease in Europe
Leuven, Belgium and Osaka, Japan (ots/PRNewswire) - - First allogeneic stem cell therapy to receive central marketing authorization approval in Europe - Alofisel offers a new treatment option for patients who do not respond to current available therapies and may be subject to numerous invasive surgeries[1] TiGenix ...
plusTakeda Pharmaceutical Company Limited
Entyvio® (vedolizumab) Shows Higher Rates of Mucosal Healing Versus TNFalpha-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease Patients in Comparative Effectiveness Real-World Data Analysis
Osaka, Japan (ots/PRNewswire) - New clinical study also provides data for Entyvio® in inducing complete mucosal healing and endoscopic remission, particularly in bio-naïve patients Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") today announced new real-world data evaluating the comparative ...
plusTakeda Pharmaceutical Company Limited
Meta-Analysis Using Real-World Data Evaluates Safety Profile of Entyvio® (vedolizumab) in Patients with Moderate to Severe Ulcerative Colitis or Crohn's Disease
Osaka, Japan (ots/PRNewswire) - New meta-analysis provides a comprehensive view of real-world data and furthers understanding of Entyvio as an important treatment option for patients with ulcerative colitis or Crohn's disease Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") today announced the ...
plusTakeda Pharmaceutical Company Limited
IBD Unmasked, a First-of-its-Kind Global Awareness Initiative, Launches to Support and Empower the Inflammatory Bowel Disease Community
Osaka, Japan (ots/PRNewswire) - Takeda unveils new IBD Super Hero and graphic illustrations, developed in collaboration with Marvel Custom Solutions, to highlight the strength of and inspire confidence in those living with IBD If someone with inflammatory bowel disease (IBD) was a Super Hero, what would that hero ...
plusSumitomo Dainippon Pharma Co Ltd and Takeda Pharmaceutical Company Limited
Sumitomo Dainippon Pharma Co. Ltd. and Takeda Pharmaceutical Company Limited Announce Decision to Terminate Their Agreement for the Joint Development and Exclusive Commercialization of Latuda® (lurasidone) - an Atypical Antipsychotic Agent, in Europe
Osaka, Japan (ots/PRNewswire) - Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon Pharma") (Head Office: Osaka, Japan: President: Masayo Tada) and Takeda Pharmaceutical Company Limited ("Takeda") (Head Office: Osaka, Japan: President and CEO: Christophe Weber) today jointly announced that their license ...
plusTakeda Pharmaceutical Company Limited
Takeda Receives European Commission Marketing Authorisation for Entyvio® (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn's Disease
Zurich And Osaka, Japan (ots/PRNewswire) - Discovery Minerals (DSCR) Undervalued and Nearing Its SqueezeTrigger Price According to WealthMakers.com Report May 27, 2014 WEALTHMAKERS.COM / www.wealthmakers.com [http://www.wealthmakers.com ] , a Wall Street research and trading firm providing unbiased statistical stock ...
plusDainippon Sumitomo Pharma Co., Ltd. and Takeda Pharmaceutical Company Limited
Dainippon Sumitomo Pharma and Takeda Announce the European Marketing Authorization for Latuda® (lurasidone) - a New Atypical Antipsychotic Medication for Adults with Schizophrenia
Osaka, Japan (ots/PRNewswire) - Dainippon Sumitomo Pharma Co., Ltd. ("DSP") (Head Office: Osaka, Japan) and Takeda Pharmaceutical Company Limited ("Takeda") (Head Office: Osaka, Japan) today jointly announced that the European Commission has granted Marketing Authorization for once-daily oral Latuda(R) (lurasidone) ...
plusTakeda Pharmaceutical Company Limited and Dainippon Sumitomo Pharma Co., Ltd.
Dainippon Sumitomo Pharma and Takeda Receive Positive CHMP Opinion for Lurasidone - a New Atypical Antipsychotic Medication for Adults with Schizophrenia
Osaka, Japan (ots/PRNewswire) - Dainippon Sumitomo Pharma Co., Ltd. ("DSP") (Head Office: Osaka, Japan) and Takeda Pharmaceutical Company Limited ("Takeda") (Head Office: Osaka, Japan) today jointly announced that the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMA), has ...
plusTakeda Pharmaceutical Company Limited
Takeda Receives Simultaneous European Marketing Authorization for Three New Type 2 Diabetes Therapies, Vipidia[TM] ? (alogliptin) and Fixed-Dose Combinations Vipdomet[TM] ? (alogliptin and metformin) and Incresync[TM] ? (alogliptin and pioglitazone)
Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical Company Limited (Takeda) today announced that the European Commission has granted Marketing Authorization (MA) for Vipidia[TM] (alogliptin), a dipeptidyl peptidase IV (DPP-4) inhibitor, for the treatment of type 2 diabetes patients who are uncontrolled on ...
plusTakeda Pharmaceutical Company Limited and Dainippon Sumitomo Pharma Co., Ltd.
DSP and Takeda Announce the Acceptance of the European Medicines Agency Submission of an Atypical Antipsychotic Agent Lurasidone
Osaka, Japan (ots/PRNewswire) - Dainippon Sumitomo Pharma Co., Ltd. ("DSP") (Headquarters: Osaka, Japan) and Takeda Pharmaceutical Company Limited ("Takeda") (Headquarters: Osaka, Japan) today announced that the European Medicines Agency (EMA) has confirmed the acceptance for review of the Marketing Authorization ...
plusTakeda Pharmaceutical Company Limited
Revestive(R) (Teduglutide) Receives European Marketing Authorization for the Treatment of Adults With Short Bowel Syndrome (SBS)
Osaka, Japan And Bedminster, New Jersey (ots/PRNewswire) - - SBS is a rare and highly disabling condition that impacts patients' quality of life and can lead to serious life-threatening complications. - Teduglutide has received orphan drug designation for the treatment of SBS from the European Medicines Agency (EMA) ...
plusTakeda Pharmaceutical Company Limited
Takeda Receives Positive CHMP Opinion for Teduglutide (Revestive®) for Patients with Short Bowel Syndrome
Osaka, Japan And Bedminster, New Jersey (ots/PRNewswire) - - European CHMP adopts positive opinion for teduglutide (Revestive(R)) for patients with short bowel syndrome (SBS) - SBS is a rare and highly disabling condition that impacts patients' quality of life and can lead to serious life-threatening complications - ...
plusTakeda Pharmaceutical Company Limited
Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
Osaka, Japan, And São Jerônimo, Brazil (ots/PRNewswire) - ? Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") and Multilab Industria e Comercio de Produtos Farmaceuticos Ltda. (Rio Grande do Sul, Brazil, "Multilab") today jointly announced that both parties have signed an agreement whereby Takeda Farmaceutica Brasil Ltda. (Sao Paulo, Brazil, "Takeda ...
plusTakeda Pharmaceutical Company Limited
Takeda Announces Acceptance of European Marketing Authorisation Application for Peginesatide, an Investigational Compound for the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis
London And Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical Company Limited (Takeda) today announced that Takeda Global Research & Development Centre (Europe) Ltd received confirmation of acceptance for assessment from the European Medicines Agency (EMA) for a Marketing Authorisation Application (MAA) for the ...
plusTakeda Pharmaceutical Company Limited
Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth
Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical Company Limited announced today strategic measures to better align its global workforce and consolidate site operations in order to integrate legacy Nycomed operations, strengthen its presence in more than 70 countries, adapt to changing market conditions and maintain a focus on growth through innovation and ...
plusTakeda Pharmaceutical Company Limited
Takeda's Edarbi® (azilsartan medoxomil) Receives European Marketing Authorisation for the Treatment of Essential Hypertension
London and Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical Company Limited (Takeda) today announced that the European Commission has granted marketing authorisation for Edarbi(R) (azilsartan medoxomil), a new once-daily angiotensin receptor blocker (ARB) (also known as angiotensin II receptor antagonist ...
plusTakeda Pharmaceutical Company Limited
Takeda Completes Acquisition and Names New CEO of Nycomed
Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical Company Limited announced it has completed its acquisition of Nycomed A/S ("Nycomed") for 9.6 billion Euro on a cash-free, debt-free basis and made Nycomed a wholly owned subsidiary of Takeda effective the same day. Dr. Frank Morich has been named CEO of Nycomed in addition to his current role as Executive Vice President (EVP), International Operations ...
plusTakeda Pharmaceutical Company Limited
Takeda Receives Positive CHMP Opinion in Europe for Edarbi(TM) (azilsartan medoxomil) for the Treatment of Essential Hypertension
London and Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical Company Limited (Takeda) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for EdarbiTM (azilsartan medoxomil, development code: TAK-491), a new ...
plus
1